G01N 2800/342
Prostate diseases
Official title: Prostate diseases, e.g. BPH, prostatitis
G01N2800/342 (Prostate diseases) appears on 38 US grants and 89 published applications in this corpus.
Search patents in G01N- Granted patents
- 38
- Published applications
- 89
- Assignees
- 54
- Inventors
- 177
- Latest grant
- 20 Aug 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 4 |
| 2005 | 1 | 8 |
| 2006 | 3 | 3 |
| 2007 | 0 | 4 |
| 2008 | 2 | 5 |
| 2009 | 0 | 3 |
| 2010 | 1 | 3 |
| 2011 | 2 | 7 |
| 2012 | 0 | 6 |
| 2013 | 2 | 5 |
| 2014 | 0 | 1 |
| 2015 | 5 | 6 |
| 2016 | 2 | 5 |
| 2017 | 2 | 5 |
| 2018 | 1 | 3 |
| 2019 | 4 | 3 |
| 2020 | 2 | 6 |
| 2021 | 4 | 0 |
| 2022 | 0 | 3 |
| 2023 | 2 | 1 |
| 2024 | 1 | 1 |
| 2025 | 0 | 2 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PSMA targeted fluorescent agents for image guided surgery20 Aug 2024US 12,065,413 B2The Johns Hopkins Universty
- PSMA-targeting compounds and uses thereof30 May 2023US 11,661,402 B2The Johns Hopkins University
- Predicting prostate cancer recurrence using a prognostic model that combines immunohistochemical staining and gene expression profiling16 May 2023US 11,651,863 B2AstraZeneca Computational Pathology GmbH
- Method and an apparatus for determining a presence or an amount of a polyamine or its derivative in a sample23 Nov 2021US 11,181,501 B2City University of Hong Kong
- Application of TRPM8 protein, related peptide fragment and their antibodies16 Nov 2021US 11,175,289 B2
- Methods for differentiating benign prostatic hyperplasia from prostate cancer24 Sep 2026US 2026/0287590 A1BPGbio, Inc.
- Braf gene fusions and uses thereof13 Aug 2026US 2026/0234694 A1Foundation Medicine, Inc.
- Method for analyzing a tumor-specific marker23 Apr 2026US 2026/0110697 A1Snipping GmbH
- Device and method for localising or identifying malignancies6 Mar 2025US 2025/0076300 A1Espire Technologies GmbH
- Biomarker for prostate cancer6 Mar 2025US 2025/0076301 A1National Taiwan University
Most cited
By later US patents
- Prostate-specific membrane antigen141US 5,538,866 ASloan-Kettering Institute for Cancer Research · 1996
- Immunoassays for prostate specific antigen110US 5,599,677 AAbbott Laboratories · 1997
- Immunoassays for prostate specific antigen63US 5,672,480 AAbbott Laboratories · 1997
- Prostate-specific membrane antigen60US 6,953,668 B1Sloan-Kettering Institute for Cancer Research · 2005
- Interstitial prostatism model animal52US 7,417,175 B2Taiho Pharmaceuticals Co., Ltd. · 2008